NASDAQ : BCAX

Bicara Therapeutics Inc. — Company profile

Healthcare · Biotechnology · United States

Last price 9.13 USD (Oct 30, 2026, 4:00 PM EST) · Market cap 604.16M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.

Details

NameBicara Therapeutics Inc.
SectorHealthcare
IndustryBiotechnology
Employees103
Founded2018
Ipo Date2024-09-13
CeoClaire Mazumdar Clemon
CountryUnited States
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUSD
Ipo Price18.00
IsinUS0554771032
Cusip055477103
Cik2023658
Sic2834
Stock TypeCommon Stock

Key executives

NameTitle
Dr. Claire Mazumdar Clemon M.B.A., Ph.D.Chief Executive Officer and Director
Ryan Cohlhepp Pharm.D.President, Chief Operating Officer and Director
Jennifer LarsonChief Financial Officer, Treasurer and Principal Accounting Officer
Rachel FrankVice President of Investor Relations and Corporate Communications
Lara S. Meisner J.D.Chief Legal Officer, Compliance Officer and Corporate Secretary
Pauline DufresneChief People Officer
Rachel SalazarSVice President of Research & Development Strategy and Operations
Sathish Hasige Ph.D.Senior Vice President and Head of Technical Operations and Supply Chain
Angela WindtVice President and Head of Regulatory Affairs
Dr. Jeltje Schulten M.B.A., M.D.Senior Vice President of Clinical and Medical Affairs

Contact

Address116 Huntington Avenue, Suite 703, Boston, Massachusetts 02116, United States
Phone617 468 4219
Websitehttps://www.bicara.com